期刊文献+

试论从中草药活性成分开发新型治疗阿尔茨海默病的酶抑制剂 被引量:1

Developing Acetylcholinesterase Inhibitors for Curing Alzheimer's Disease from Active Constituents of Chinese Herbal Medicines
下载PDF
导出
摘要 根据阿尔茨海默病发病机理的胆碱能假说及其最新的生理及病理学研究结果,对现有临床治疗阿尔茨海默病的乙酰胆碱酯酶抑制剂药物的特点及应用进行了概括和总结;根据中医药治疗老年痴呆及有关研究的现状,特别通过一些中药经体外酶抑制活性实验结果,论述从中草药活性成分开发新型治疗阿尔茨海默病抑制剂药物的趋势、方向及必要性和可行性。 According to the suppositions on disease function of Alzheimer' s disease(AD) and it's new research results of physiology and pathology ,the characteristic and application of acetylcholinesterase inhibitors for treating AD in clinic were surveyed. In conjuction with present coditions of curing AD by traditional Chinese medica and basease on the test results of inhibit - acetylcholinesterasc out - body, the feasibility and necessity for develop new AD drugs of acctylcholinesterasc inhibitors from active constituents in Chinese herb medicines were recommended.
作者 金虹
出处 《时珍国医国药》 CAS CSCD 北大核心 2006年第1期19-20,共2页 Lishizhen Medicine and Materia Medica Research
基金 西南科技大学重大科技研究项目资助(No.ZK033129)
关键词 阿尔茨海默病 胆碱酯酶抑制刑 中草药 中医药 活性组分 Alzheimer' s disease ( AD ) Acetylcholinesterase inhibitors Chinese herb medicines Traditional Chinese medica Active constituents
  • 相关文献

参考文献18

  • 1Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population :prevalence estimates using the 2000 Census[ J ]. Arch Neurol. 2003:60:1119.
  • 2Coyle Jr, Price DL, Delong MR. Alzheimer disease : a disorder of cortical cholinergic innervation[ J ]. Science. 1983,219 : 1184.
  • 3Iqbal K. Alzheimer' s disease : Biology, Diagmosis and Therapeutics[ M]. New York:John Wiley & sons Ltd,1997. 500.
  • 4Hardyj, Selkae DJ. The amyloid hypothesis of Alzheimer' s disease : progress and problems on the road to therapeutics[J]. Science 2002,297 :353 [ Erratum, Science 2002,297:2209 ].
  • 5Pappas BA, Bayley PJ, Bui BK, et al. Choline acetylty ansferase activityand cognitive domain scores of Alzheimer' s Patients [ J ], Neuro Aging 2000,21:11.
  • 6Palmer AM, Stratrnann GC, Procter AW, et al. Possible neurotransmitter basis of behavioral changes in Alzheimer' s disease [ J ]. Ann Neurol 1988,23:616.
  • 7Doody RS, Stevens JC, Beck C, et al, Practice parameter: management of dementia( an evidence - based review) : report of the Quality Standards Subcommittee of the American Academy of Neurdogy [ J ]. Neurology 2001 ;56:1154.
  • 8Xiao XQ, Wang R, Han YF, et al. Protective effects of huperzine A on betaamyloid(25 -35 )induced oxidative injury in rat pheochromecy toma cells [ J ]. Neurosci lett ,2000,286 ( 3 ) : 155.
  • 9Pettigrew LC, Bieber r, LettierJ, et al. Pharmacokinetics, pharmacodynamies, and safety of metrifonate in patients with Alzheimer' s disease[ J ]. J Clin pharmacol, 1998,38 ;236.
  • 10韩怡凡 PaulRCarlier 唐希灿.“中西交融”治疗阿尔采默病-从石杉碱甲到乙酰胆碱酯酶新型二聚体抑制剂[A]..中药研究与开发综述一香港科技大学生物技术研究所访问学者文集[C].北京:科学出版社,2000.162.

共引文献13

同被引文献10

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部